par Agathe Masson | Déc 9, 2024 | Access to Care, NCD Solutions, Actualités
Sickle Cell Disease (SCD) is a genetic blood disorder that affects millions of people worldwide. Between 2010 and 2050, an estimated 14 million babies will be affected globally, with the vast majority born in low- and middle-income countries (LMICs). This staggering...
par Agathe Masson | Déc 9, 2024 | Access to Care, NCD Policy, Actualités
Access to essential treatments is a cornerstone of effective healthcare systems. Both brand-name medicines and generics play vital roles in ensuring that patients receive the care they need. While brand-name medicines are often associated with innovation and...
par Agathe Masson | Déc 9, 2024 | Access to Care, NCD Financing, Actualités
Success in improving access to cancer care is not about a one-size-fits-all approach; it involves addressing unmet needs with high-impact actions. In its comprehensive white paper, Improving Access to Affordable and Sustainable Oncological Care in Africa, IQVIA...
par Callie Weber | Avr 15, 2024 | Access to Care, NCD Partnerships, Actualités
IDA Foundation and FIND have joined forces to help address the challenges of availability, affordability, and optimal use of diagnostics for Noncommunicable Diseases (NCDs) in low- and middle-income countries (LMICs). IDA Foundation and FIND Partner to Deliver NCD...
par Callie Weber | Mar 13, 2024 | Access to Care, NCD Partnerships, Actualités
In a significant stride towards addressing the global challenge of Noncommunicable Diseases (NCDs), IDA Foundation and the Coalition for Access to NCD Medicines & Products are proud to announce their partnership. NCDs, encompassing chronic conditions such as...
par Agathe Masson | Fév 5, 2024 | Access to Care, NCD Partnerships, Actualités
IDA Foundation and the Access to Oncology Medicines (ATOM) Coalition are happy to announce their strategic partnership. Following World Cancer Day’s theme ‘Close the Care Gap’, this collaboration marks a significant step toward addressing the challenges of...
